ERVW-1 and infection: We analysed HIV-1 Env sequences from the RV144 trial, including 44 vaccine-breakthrough infections (infections in the vaccine arm), and viruses from 66 infected individuals from the placebo group, in order to select additional Envs that improve HIV Env sequence coverage in the Thai population and could complement the bivalent protein component of the RV144 vaccine.